0001157523-23-000815.txt : 20230511 0001157523-23-000815.hdr.sgml : 20230511 20230511060724 ACCESSION NUMBER: 0001157523-23-000815 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20230511 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20230511 DATE AS OF CHANGE: 20230511 FILER: COMPANY DATA: COMPANY CONFORMED NAME: REVVITY, INC. CENTRAL INDEX KEY: 0000031791 STANDARD INDUSTRIAL CLASSIFICATION: LABORATORY ANALYTICAL INSTRUMENTS [3826] IRS NUMBER: 042052042 STATE OF INCORPORATION: MA FISCAL YEAR END: 1229 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-05075 FILM NUMBER: 23908661 BUSINESS ADDRESS: STREET 1: 940 WINTER STREET CITY: WALTHAM STATE: MA ZIP: 02451 BUSINESS PHONE: 781-663-5791 MAIL ADDRESS: STREET 1: 940 WINTER STREET CITY: WALTHAM STATE: MA ZIP: 02451 FORMER COMPANY: FORMER CONFORMED NAME: PERKINELMER INC DATE OF NAME CHANGE: 19991103 FORMER COMPANY: FORMER CONFORMED NAME: EG&G INC DATE OF NAME CHANGE: 19920703 FORMER COMPANY: FORMER CONFORMED NAME: EDGERTON GERMESHAUSEN & GRIER INC DATE OF NAME CHANGE: 19670626 8-K 1 a53397725.htm REVVITY, INC. 8-K
 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

 

FORM 8-K
 
 
 
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
 
Date of Report (Date of earliest event reported): May 11, 2023

 

Revvity, Inc.
(Exact Name of Registrant as Specified in its Charter)

 
 
Massachusetts
001-05075
04-2052042
(State or Other Jurisdiction
of Incorporation or Organization)
(Commission
File Number)
(IRS Employer
Identification No.)
 
940 Winter Street, Waltham, Massachusetts
02451
(Address of Principal Executive Offices)
(Zip Code)
 
Registrant’s telephone number, including area code: (781) 663-6900
 
Not applicable
(Former Name or Former Address, if Changed Since Last Report)

 
 
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐  Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐  Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐  Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐  Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class
   Trading Symbol(s)
   Name of exchange on which registered
Common stock, $1 par value per share
  
PKI
  
The New York Stock Exchange
1.875% Notes due 2026
  
PKI 21A
  
The New York Stock Exchange

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
 
Emerging growth company   ☐
 
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐
Item 2.02.  Results of Operations and Financial Condition

On May 11, 2023, Revvity, Inc. announced its financial results for the first quarter ended April 2, 2023.  The full text of the press release issued in connection with the announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

The information in this Form 8-K (including Exhibit 99.1) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such a filing.
 
Item 9.01.  Financial Statements and Exhibits

(d)            Exhibits

EXHIBIT INDEX

   
Exhibit No.
Description
 
 
  
104
Cover Page Interactive Data File (embedded within the Inline XBRL)

* This exhibit relating to Item 2.02 shall be deemed to be furnished, and not filed.
 
SIGNATURE
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
 
REVVITY, INC.
Date: May 11, 2023
By: /s/ Maxwell Krakowiak
Maxwell Krakowiak
Senior Vice President and Chief Financial Officer

 
 EX-99.1 2 a53397725ex99_1.htm EXHIBIT 99.1
Exhibit 99.1

Revvity Announces Financial Results for the First Quarter of 2023

  • Revenue of $675 million; (30)% reported growth; (27)% organic growth; 6% non-COVID organic growth
  • GAAP EPS of $4.50; Adjusted EPS from continuing operations of $1.01
  • Updates full year 2023 guidance
  • Authorizes new $600 million share repurchase program
  • To begin trading under new ticker “RVTY” on May 16th

WALTHAM, Mass.--(BUSINESS WIRE)--May 11, 2023--Revvity, Inc. (NYSE: PKI), today reported financial results for the first quarter ended April 2, 2023.

The Company reported GAAP earnings per share of $4.50, as compared to $1.40 in the same period a year ago. GAAP revenue for the quarter was $675 million, as compared to $963 million in the same period a year ago. GAAP operating income for the quarter was $76 million, as compared to $262 million for the same period a year ago. GAAP operating profit margin was 11.3% as a percentage of revenue, as compared to 27.2% in the same period a year ago.

Adjusted earnings per share from continuing operations for the quarter was $1.01, as compared to $2.30 in the same period a year ago. Adjusted revenue for the quarter was $675 million, as compared to $963 million in the same period a year ago. Adjusted operating income was $189 million, as compared to $393 million for the same period a year ago. Adjusted operating profit margin was 28.0% as a percentage of adjusted revenue, as compared to 40.8% in the same period a year ago.

Adjustments for the Company's non-GAAP financial measures have been noted in the attached reconciliations.

“Revvity has tremendous potential as we enter this new phase of our company’s journey,” said Prahlad Singh, president and chief executive officer of Revvity. “Our strong first quarter results demonstrate our consistent and high level of execution and set us on a positive path as we begin this next chapter in our transformation.”

Stock Ticker Change

The Company’s stock ticker will change from PKI to RVTY with the beginning of trading on May 16, 2023. Members of the Revvity team will ring the opening bell of the New York Stock Exchange that morning to commemorate the launch of the Company’s new corporate name and brand, and to celebrate initial trading under the new stock ticker. A livestream of the ceremony can be viewed at www.nyse.com/bell with videos and photos from the day to be provided on our social media channels.

Financial Overview by Reporting Segment for the First Quarter

Life Sciences

  • First quarter 2023 revenue was $328 million, as compared to $306 million in the same period a year ago. Reported revenue increased 7% and organic revenue increased 9% as compared to the same period a year ago.
  • First quarter 2023 adjusted operating income was $129 million, as compared to $110 million in the same period a year ago.
  • First quarter 2023 adjusted operating profit margin was 39.4% as a percentage of adjusted revenue, as compared to 36.0% in the same period a year ago.

Diagnostics

  • First quarter 2023 revenue was $347 million, as compared to $657 million in the same period a year ago. Reported revenue decreased 47% and organic revenue decreased 44% as compared to the same period a year ago.
  • First quarter 2023 adjusted operating income was $74 million, as compared to $301 million in the same period a year ago.
  • First quarter 2023 adjusted operating profit margin was 21.5% as a percentage of adjusted revenue, as compared to 45.8% in the same period a year ago.

Updates Full Year 2023 Guidance

For the full year 2023, the Company now forecasts total revenue of $2.90-$2.94 billion and adjusted earnings per share of $4.85-$5.05. This guidance assumes no additional contribution from COVID related revenues.

Guidance for the full year 2023 is provided on a non-GAAP basis and cannot be reconciled to the closest GAAP measures without unreasonable effort due to the unpredictability of the amounts and timing of events affecting the items the Company excludes from these non-GAAP measures. The timing and amounts of such events and items could be material to the Company’s results prepared in accordance with GAAP.

Webcast Information

The Company will discuss its first quarter 2023 results and its outlook for business trends during a webcast on May 11, 2023, at 8:00 a.m. Eastern Time. A live audio webcast and presentation will be available on the Investors section of the Company’s website, ir.revvity.com.

Use of Non-GAAP Financial Measures

In addition to financial measures prepared in accordance with generally accepted accounting principles (GAAP), this earnings announcement also contains non-GAAP financial measures. The reasons that we use these measures, a reconciliation of these measures to the most directly comparable GAAP measures, and other information relating to these measures are included below following our GAAP financial statements.

Factors Affecting Future Performance

This press release contains "forward-looking" statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements relating to estimates and projections of future earnings per share, cash flow and revenue growth and other financial results, developments relating to our customers and end-markets, and plans concerning business development opportunities, acquisitions and divestitures. Words such as "believes," "intends," "anticipates," "plans," "expects," “estimates”, "projects," "forecasts," "will" and similar expressions, and references to guidance, are intended to identify forward-looking statements. Such statements are based on management's current assumptions and expectations and no assurances can be given that our assumptions or expectations will prove to be correct. A number of important risk factors could cause actual results to differ materially from the results described, implied or projected in any forward-looking statements. These factors include, without limitation: (1) markets into which we sell our products declining or not growing as anticipated; (2) the effect of the COVID-19 pandemic on our sales and operations; (3) fluctuations in the global economic and political environments; (4) our failure to introduce new products in a timely manner; (5) our ability to execute acquisitions and divestitures, license technologies, or to successfully integrate acquired businesses and licensed technologies into our existing business or to make them profitable, or successfully divest businesses; (6) our ability to compete effectively; (7) fluctuation in our quarterly operating results and our ability to adjust our operations to address unexpected changes; (8) significant disruption in third-party package delivery and import/export services or significant increases in prices for those services; (9) disruptions in the supply of raw materials and supplies; (10) our ability to retain key personnel; (11) significant disruption in our information technology systems, or cybercrime; (12) our ability to realize the full value of our intangible assets; (13) our failure to adequately protect our intellectual property; (14) the loss of any of our licenses or licensed rights; (15) the manufacture and sale of products exposing us to product liability claims; (16) our failure to maintain compliance with applicable government regulations; (17) regulatory changes; (18) our failure to comply with healthcare industry regulations; (19) economic, political and other risks associated with foreign operations; (20) our ability to obtain future financing; (21) restrictions in our credit agreements; (22) significant fluctuations in our stock price; (23) reduction or elimination of dividends on our common stock; and (24) other factors which we describe under the caption "Risk Factors" in our most recent annual report on Form 10-K and in our other filings with the Securities and Exchange Commission. We disclaim any intention or obligation to update any forward-looking statements as a result of developments occurring after the date of this press release.

About Revvity

At Revvity, “impossible” is inspiration, and “can’t be done” is a call to action. Revvity provides health science solutions, technologies, expertise and services that deliver complete workflows from discovery to development, and diagnosis to cure. Revvity is revolutionizing what’s possible in healthcare, with specialized focus areas in translational multi-omics technologies, biomarker identification, imaging, prediction, screening, detection and diagnosis, informatics and more.

With more than $3 billion in revenue and over 11,000 employees, Revvity serves customers across pharmaceutical and biotech, diagnostic labs, academia and governments. It is part of the S&P 500 index and has customers in more than 190 countries.

Stay updated by following our Newsroom, LinkedIn, Twitter, YouTube, Facebook and Instagram for updates.


Revvity, Inc. and Subsidiaries

CONDENSED CONSOLIDATED INCOME STATEMENTS




 




 



Three Months Ended



(In thousands, except per share data)
April 2, 2023
April 3, 2022










 

Revenue

$

674,865

 


$

963,163

 












 

Cost of revenue

 

293,499

 


 

368,423

 



Selling, general and administrative expenses

 

248,557

 


 

275,260

 



Research and development expenses

 

56,690

 


 

57,524

 












 

Operating income from continuing operations

 

76,119

 


 

261,956

 












 

Interest income

 

(5,272

)


 

(595

)



Interest expense

 

22,738

 


 

28,388

 



Change in fair value of financial securities

 

(2,768

)


 

12,124

 



Other expense (income), net

 

31,981

 


 

(2,865

)












 

Income from continuing operations, before income taxes

 

29,440

 


 

224,904

 












 

Provision for income taxes

 

4,595

 


 

40,834

 












 

Income from continuing operations

 

24,845

 


 

184,070

 












 

Income (loss) from discontinued operations

 

544,630

 


 

(7,108

)












 

Net income

$

569,475

 


$

176,962

 












 










 

Diluted earnings per share:





Income from continuing operations

$

0.20

 


$

1.45

 












 

Income (loss) from discontinued operations

 

4.31

 


 

(0.06

)












 

Net income

$

4.50

 


$

1.40

 












 

Weighted average diluted shares of common stock outstanding

 

126,469

 


 

126,635

 








 

ABOVE PREPARED IN ACCORDANCE WITH GAAP













 








Additional supplemental information (1):





(per share, continuing operations)














 

GAAP EPS from continuing operations

$

0.20

 


$

1.45

 



Amortization of intangible assets

 

0.73

 


 

0.75

 



Debt extinguishment costs

 

(0.03

)


 

0.00

 



Purchase accounting adjustments

 

(0.01

)


 

0.14

 



Acquisition and divestiture-related costs

 

0.35

 


 

0.07

 



Change in fair value of financial securities

 

(0.02

)


 

0.10

 



Significant litigation matters and settlements

 

-

 


 

0.00

 



Significant environmental matters

 

0.01

 


 

-

 



Restructuring and other, net

 

0.02

 


 

0.07

 



Tax on above items

 

(0.23

)


 

(0.28

)



Significant tax items

 

(0.01

)


 

-

 



Adjusted EPS from continuing operations

$

1.01

 


$ 

2.30

 












 

(1) amounts may not sum due to rounding


















Revvity, Inc. and Subsidiaries
REVENUE AND OPERATING INCOME (LOSS)


 


 


Three Months Ended
(In thousands, except percentages)
April 2, 2023
April 3, 2022




 
Adjusted revenue and operating income







 
Reported revenue

$

674,865

 


$

963,163

 

Revenue purchase accounting adjustments

 

206

 


 

203

 

Adjusted revenue

 

675,071

 


 

963,366

 







 
Reported operating income from continued operations

 

76,119

 


 

261,956

 

OP%

 

11.3

%


 

27.2

%

Amortization of intangible assets

 

91,811

 


 

95,213

 

Purchase accounting adjustments

 

(914

)


 

18,004

 

Acquisition and divestiture-related costs

 

17,951

 


 

8,817

 

Significant litigation matters and settlements

 

-

 


 

425

 

Significant environmental matters

 

1,132

 


 

-

 

Restructuring and other, net

 

3,095

 


 

8,983

 

Adjusted operating income

$

189,194

 


$

393,398

 

OP%

 

28.0

%


 

40.8

%





 
Segment revenue and segment operating income









 
Life Sciences

$

328,441

 


$

306,087

 

Diagnostics

 

346,630

 


 

657,279

 

Revenue purchase accounting adjustments

 

(206

)


 

(203

)

Reported revenue

 

674,865

 


 

963,163

 







 






 
Life Sciences

 

129,459

 


 

110,181

 



 

39.4

%


 

36.0

%

Diagnostics

 

74,432

 


 

300,899

 



 

21.5

%


 

45.8

%

Corporate

 

(14,697

)


 

(17,682

)

Subtotal reportable segments operating income

 

189,194

 


 

393,398

 







 
Amortization of intangible assets

 

(91,811

)


 

(95,213

)

Purchase accounting adjustments

 

914

 


 

(18,004

)

Acquisition and divestiture-related costs

 

(17,951

)


 

(8,817

)

Significant litigation matters and settlements

 

-

 


 

(425

)

Significant environmental matters

 

(1,132

)


 

-

 

Restructuring and other, net

 

(3,095

)


 

(8,983

)

Reported operating income from continued operations

$

76,119

 


$

261,956

 







 

REPORTED REVENUE AND REPORTED OPERATING INCOME (LOSS) PREPARED IN ACCORDANCE WITH GAAP







Revvity, Inc. and Subsidiaries
CONDENSED CONSOLIDATED BALANCE SHEETS



 



 
(In thousands) April 2, 2023
January 1, 2023



 
Current assets:


Cash and cash equivalents

$

2,267,183


$

454,358

Marketable securities

 

193,963


 

-

Accounts receivable, net

 

586,922


 

612,780

Inventories, net

 

429,423


 

405,462

Other current assets

 

318,116


 

122,254

Current assets of discontinued operations

 

-


 

1,693,704

Total current assets

 

3,795,607


 

3,288,558




 
Property, plant and equipment, net

 

491,162


 

482,950

Operating lease right-of-use assets

 

167,905


 

188,351

Intangible assets, net

 

3,294,657


 

3,377,174

Goodwill

 

6,505,956


 

6,481,768

Other assets, net

 

382,868


 

311,054

Total assets

$

14,638,155


$

14,129,855




 
Current liabilities:


Current portion of long-term debt

$

479,423


$

470,929

Accounts payable

 

266,884


 

272,826

Accrued expenses and other current liabilities

 

817,432


 

527,863

Current liabilities of discontinued operations

 

-


 

272,865

Total current liabilities

 

1,563,739


 

1,544,483




 
Long-term debt

 

3,880,984


 

3,923,347

Long-term liabilities

 

1,010,230


 

1,109,181

Operating lease liabilities

 

149,392


 

169,968

Total liabilities

 

6,604,345


 

6,746,979




 
Total stockholders' equity

 

8,033,810


 

7,382,876

Total liabilities and stockholders' equity

$

14,638,155


$

14,129,855




 

PREPARED IN ACCORDANCE WITH GAAP




 

Revvity, Inc. and Subsidiaries
CONSOLIDATED STATEMENTS OF CASH FLOWS

 

 

Three Months Ended

April 2, 2023
April 3, 2022

(In thousands)




Operating activities:


Net income

$

569,475

 


$

176,962

 

(Income) loss from discontinued operations, net of income taxes

 

(544,630

)


 

7,108

 

Income from continuing operations

 

24,845

 


 

184,070

 

Adjustments to reconcile income from continuing operations


to net cash provided by continuing operations:


Stock-based compensation

 

9,893

 


 

14,438

 

Restructuring and other, net

 

3,096

 


 

8,983

 

Depreciation and amortization

 

109,008

 


 

109,330

 

Change in fair value of contingent consideration

 

(1,360

)


 

693

 

Amortization of deferred debt financing costs and accretion of discounts

 

1,792

 


 

1,781

 

Change in fair value of financial securities

 

(2,768

)


 

12,125

 

Debt extinguishment (income) loss

 

(3,345

)


 

119

 

Unrealized foreign exchange loss

 

26,095

 


 

-

 

Amortization of acquired inventory revaluation

 

-

 


 

16,868

 

Changes in assets and liabilities which provided (used) cash, excluding


effects from companies acquired:


Accounts receivable, net

 

34,424

 


 

77,398

 

Inventories

 

(18,520

)


 

(20,943

)

Accounts payable

 

(4,895

)


 

26,739

 

Accrued expenses and other

 

(106,591

)


 

(105,480

)

Net cash provided by operating activities of continuing operations

 

71,674

 


 

326,121

 

Net cash used in operating activities of discontinued operations

 

(8,211

)


 

(42,906

)

Net cash provided by operating activities

 

63,463

 


 

283,215

 




 
Investing activities:


Capital expenditures

 

(20,946

)


 

(26,969

)

Purchases of investments

 

-

 


 

(18,000

)

Purchases of marketable securities

 

(193,454

)


 

-

 

Cash paid for acquisitions, net of cash, cash equivalents and restricted cash acquired

 

(686

)


 

(3,630

)

Net cash used in investing activities of continuing operations

 

(215,086

)


 

(48,599

)

Net cash provided by (used in) investing activities of discontinued operations

 

2,079,588

 


 

(7,707

)

Net cash provided by (used in) investing activities

 

1,864,502

 


 

(56,306

)




 
Financing Activities:


Payments on borrowings

 

-

 


 

(220,000

)

Proceeds from borrowings

 

-

 


 

220,000

 

Payments of term loan

 

-

 


 

(100,000

)

Payments of senior debt

 

(49,603

)


 

-

 

Settlement of cash flow hedges

 

-

 


 

(762

)

Net proceeds (payments) on other credit facilities

 

7,867

 


 

(1,064

)

Payments for acquisition-related contingent consideration

 

(1,475

)


 

-

 

Proceeds from issuance of common stock under stock plans

 

523

 


 

1,397

 

Purchases of common stock

 

(61,656

)


 

(55,592

)

Dividends paid

 

(8,841

)


 

(8,837

)

Net cash used in financing activities

 

(113,185

)


 

(164,858

)








 
Effect of exchange rate changes on cash, cash equivalents, and restricted cash

 

(16,969

)


 

(10,636

)








 
Net increase in cash, cash equivalents, and restricted cash

 

1,797,811

 


 

51,415

 

Cash, cash equivalents, and restricted cash at beginning of period

 

470,746

 


 

619,337

 

Cash, cash equivalents, and restricted cash at end of period

$

2,268,557

 


$

670,752

 








 



 
Supplemental disclosure of cash flow information:


Reconciliation of cash, cash equivalents and restricted cash reported within the consolidated balance sheets that sum to the total shown in the consolidated statements of cash flows:


Cash and cash equivalents

$

2,267,183

 


$

654,756

 

Restricted cash included in other current assets

 

1,019

 


 

997

 

Restricted cash included in other assets

 

355

 


 

-

 

Cash and cash equivalents included in current assets of discontinued operations

 

-

 


 

14,999

 

Total cash, cash equivalents and restricted cash

$

2,268,557

 


$

670,752

 




 

PREPARED IN ACCORDANCE WITH GAAP





Revvity, Inc. and Subsidiaries
RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL MEASURES (1)



 



 

Revvity


Three Months Ended


April 2, 2023
Organic revenue growth:


Reported revenue growth from continuing operations

-30%


Less: effect of foreign exchange rates

-3%


Less: effect of acquisitions including purchase accounting adjustments and impact of divested businesses

0%


Organic revenue growth from continuing operations

-27%


Less: effect of COVID products

-33%


Non-COVID organic revenue growth from continuing operations

6%





 



 

Life Sciences


Three Months Ended


April 2, 2023
Organic revenue growth:


Reported revenue growth from continuing operations

7%


Less: effect of foreign exchange rates

-2%


Less: effect of acquisitions including purchase accounting adjustments and impact of divested businesses

0%


Organic revenue growth from continuing operations

9%





 



 

Diagnostics


Three Months Ended


April 2, 2023
Organic revenue growth:


Reported revenue growth from continuing operations

-47%


Less: effect of foreign exchange rates

-3%


Less: effect of acquisitions including purchase accounting adjustments and impact of divested businesses

0%


Organic revenue growth from continuing operations

-44%


Less: effect of COVID products

-47%


Non-COVID organic revenue growth from continuing operations

3%





 
(1) amounts may not sum due to rounding


Explanation of Non-GAAP Financial Measures

We report our financial results in accordance with GAAP. However, management believes that, in order to more fully understand our short-term and long-term financial and operational trends, investors may wish to consider the impact of certain non-cash, non-recurring or other items, which result from facts and circumstances that vary in frequency and impact on continuing operations. Accordingly, we present non-GAAP financial measures as a supplement to the financial measures we present in accordance with GAAP. These non-GAAP financial measures provide management with additional means to understand and evaluate the operating results and trends in our ongoing business by adjusting for certain non-cash expenses and other items that management believes might otherwise make comparisons of our ongoing business with prior periods more difficult, obscure trends in ongoing operations, or reduce management's ability to make useful forecasts. Management believes these non-GAAP financial measures provide additional means of evaluating period-over-period operating performance. In addition, management understands that some investors and financial analysts find this information helpful in analyzing our financial and operational performance and comparing this performance to our peers and competitors.

We use the term “adjusted revenue” to refer to GAAP revenue, including purchase accounting adjustments for revenue from contracts acquired in acquisitions that will not be fully recognized due to accounting rules. We use the related term “adjusted revenue growth” to refer to the measure of comparing current period adjusted revenue with the corresponding period of the prior year.

We use the term “organic revenue” to refer to GAAP revenue, excluding the effect of foreign currency changes and revenue from recent acquisitions and divestitures and including purchase accounting adjustments for revenue from contracts acquired in acquisitions that will not be fully recognized due to accounting rules. We use the related term “organic revenue growth” to refer to the measure of comparing current period organic revenue with the corresponding period of the prior year. We use the related term “non-COVID organic revenue growth” to refer to the measure of comparing current period organic revenue excluding revenue from COVID related products and services with the corresponding period of the prior year excluding revenue from COVID related products and services.

We use the term “adjusted gross margin” to refer to GAAP gross margin, excluding amortization of intangible assets and inventory fair value adjustments related to business acquisitions, asset impairments, and including purchase accounting adjustments for revenue from contracts acquired in acquisitions that will not be fully recognized due to business combination accounting rules. We use the related term “adjusted gross margin percentage” to refer to adjusted gross margin as a percentage of adjusted revenue.

We use the term “adjusted SG&A expense” to refer to GAAP SG&A expense, excluding amortization of intangible assets, purchase accounting adjustments, acquisition and divestiture-related expenses, significant litigation matters and settlements, asset impairments, and significant environmental charges. We use the related term “adjusted SG&A percentage” to refer to adjusted SG&A expense as a percentage of adjusted revenue.

We use the term “adjusted R&D expense” to refer to GAAP R&D expense, excluding amortization of intangible assets and purchase accounting adjustments. We use the related term “adjusted R&D percentage” to refer to adjusted R&D expense as a percentage of adjusted revenue.

We use the term “adjusted net interest and other expense” to refer to GAAP net interest and other expense, excluding adjustments for mark-to-market accounting on post-retirement benefits, changes in foreign exchange associated with acquisitions and divestitures, changes in the value of financial securities and debt extinguishment costs.

We use the term “adjusted operating income,” to refer to GAAP operating income, including revenue from contracts acquired in acquisitions that will not be fully recognized due to accounting rules, and excluding amortization of intangible assets, other purchase accounting adjustments, acquisition and divestiture-related expenses, significant litigation matters and settlements, significant environmental charges, asset impairments, and restructuring and other charges. We use the related terms “adjusted operating profit percentage,” “adjusted operating profit margin,” or “adjusted operating margin” to refer to adjusted operating income as a percentage of adjusted revenue.

We use the term “adjusted earnings per share,” or “adjusted EPS,” to refer to GAAP earnings per share, including revenue from contracts acquired in acquisitions that will not be fully recognized due to accounting rules, and excluding discontinued operations, amortization of intangible assets, debt extinguishment costs, other purchase accounting adjustments, acquisition and divestiture-related expenses, significant litigation matters and settlements, significant environmental charges, changes in the value of financial securities, disposition of businesses and assets, net, changes in foreign exchange associated with acquisitions and divestitures, asset impairments and restructuring and other charges. We also exclude adjustments for mark-to-market accounting on post-retirement benefits, therefore only our projected costs have been used to calculate this non-GAAP measure. We also adjust for any tax impact related to the above items and exclude the impact of significant tax events.

We use the term “adjusted earnings per share from continuing operations,” to refer to GAAP earnings per share from continuing operations, including revenue from contracts acquired in acquisitions that will not be fully recognized due to accounting rules, amortization of intangible assets, debt extinguishment costs, other purchase accounting adjustments, acquisition and divestiture-related expenses, significant litigation matters and settlements, significant environmental charges, changes in the value of financial securities, disposition of businesses and assets, net, changes in foreign exchange associated with acquisitions and divestitures, asset impairments and restructuring and other charges. We also exclude adjustments for mark-to-market accounting on post-retirement benefits, therefore only our projected costs have been used to calculate this non-GAAP measure. We also adjust for any tax impact related to the above items and exclude the impact of significant tax events.

Management includes or excludes the effect of each of the items identified below in the applicable non-GAAP financial measure referenced above for the reasons set forth below with respect to that item:

  • Amortization of intangible assets— purchased intangible assets are amortized over their estimated useful lives and generally cannot be changed or influenced by management after the acquisition. Accordingly, this item is not considered by management in making operating decisions. Management does not believe such charges accurately reflect the performance of our ongoing operations for the period in which such charges are incurred.
  • Debt extinguishment costs—we incur costs and income related to the extinguishment of debt; including make-whole payments to debt holders, accelerated amortization of debt fees and discounts, and expense or income from hedges to lock in make-whole payments. We exclude the impact of these items from our non-GAAP measures because we believe they do not reflect the performance of our ongoing operations.
  • Revenue from contracts acquired in acquisitions that will not be fully recognized due to accounting rules— accounting rules require us to account for the fair value of revenue from contracts assumed in connection with our acquisitions. As a result, our GAAP results reflect the fair value of those revenues, which is not the same as the revenue that otherwise would have been recorded by the acquired entity. We include such revenue in our non-GAAP measures because we believe the fair value of such revenue does not accurately reflect the performance of our ongoing operations for the period in which such revenue is recorded.
  • Other purchase accounting adjustments—accounting rules require us to adjust various balance sheet accounts, including inventory, fixed assets and deferred rent balances to fair value at the time of the acquisition. As a result, the expenses for these items in our GAAP results are not the same as what would have been recorded by the acquired entity. Accounting rules also require us to estimate the fair value of contingent consideration at the time of the acquisition, and any subsequent changes to the estimate or payment of the contingent consideration and purchase accounting adjustments are charged to expense or income. We exclude the impact of any changes to contingent consideration from our non-GAAP measures because we believe these expenses or benefits do not accurately reflect the performance of our ongoing operations for the period in which such expenses or benefits are recorded.
  • Acquisition and divestiture-related expenses—we incur legal, due diligence, stay bonuses, incentive awards, stock-based compensation, interest expense, foreign exchange gains and losses, integration expenses and other costs related to acquisitions and divestitures. We exclude these expenses from our non-GAAP measures because we believe they do not reflect the performance of our ongoing operations.
  • Asset impairments—we incur expense related to asset impairments. Management does not believe such charges accurately reflect the performance of our ongoing operations for the periods in which such charges were incurred.
  • Restructuring and other charges—restructuring and other charges consist of employee severance, other exit costs as well as the cost of terminating certain lease agreements or contracts as well as costs associated with relocating facilities. Management does not believe such costs accurately reflect the performance of our ongoing operations for the period in which such costs are reported.
  • Adjustments for mark-to-market accounting on post-retirement benefits—we exclude adjustments for mark-to-market accounting on post-retirement benefits, and therefore only our projected costs are used to calculate our non-GAAP measures. We exclude these adjustments because they do not represent what we believe our investors consider to be costs of producing our products, investments in technology and production, and costs to support our internal operating structure.
  • Significant litigation matters and settlements—we incur expenses related to significant litigation matters, including the costs to settle or resolve various claims and legal proceedings. Management does not believe such charges accurately reflect the performance of our ongoing operations for the periods in which such charges were incurred.
  • Significant environmental charges—we incur expenses related to significant environmental charges. Management does not believe such charges accurately reflect the performance of our ongoing operations for the periods in which such charges were incurred.
  • Disposition of businesses and assets, net—we exclude the impact of gains or losses from the disposition of businesses and assets from our adjusted earnings per share. Management does not believe such gains or losses accurately reflect the performance of our ongoing operations for the period in which such gains or losses are reported.
  • Impact of foreign currency changes on the current period— we exclude the impact of foreign currency associated with acquisitions and divestitures from these measures by using the prior period’s foreign currency exchange rates for the current period because foreign currency exchange rates are subject to volatility and can obscure underlying trends.
  • Impact of significant tax events—we exclude the impact of significant tax events, such as the Tax Cuts and Jobs Act of 2017. Management does not believe the impact of significant tax events accurately reflects the performance of our ongoing operations for the periods in which the impact of such events was recorded.
  • Changes in value of financial securities—we exclude the impact of changes in the value of financial securities. Management does not believe such gains or losses accurately reflect the performance of our ongoing operations for the period in which such gains or losses are reported.
  • Depreciation of fixed assets ceased upon reporting the business as held for sale—we exclude the impact of ceasing depreciation of fixed assets that are held for sale. Management does not believe such charges accurately reflect the performance of our ongoing operations for the periods in which such expenses were ceased.

# # #

The tax effect for discontinued operations is calculated based on the authoritative guidance in the Financial Accounting Standards Board’s Accounting Standards Codification 740, Income Taxes. The tax effect for amortization of intangible assets, inventory fair value adjustments related to business acquisitions, changes to the fair values assigned to contingent consideration, debt extinguishment costs, other costs related to business acquisitions and divestitures, significant litigation matters and settlements, significant environmental charges, changes in the fair value of financial securities, adjustments for mark-to-market accounting on post-retirement benefits, disposition of businesses and assets, net, restructuring and other charges, and the revenue from contracts acquired with various acquisitions is calculated based on operational results and applicable jurisdictional law, which contemplates tax rates currently in effect to determine our tax provision. The tax effect for the impact from foreign currency exchange rates on the current period is calculated based on the average rate currently in effect to determine our tax provision.

The non-GAAP financial measures described above are not meant to be considered superior to, or a substitute for, our financial statements prepared in accordance with GAAP. There are material limitations associated with non-GAAP financial measures because they exclude charges that have an effect on our reported results and, therefore, should not be relied upon as the sole financial measures by which to evaluate our financial results. Management compensates and believes that investors should compensate for these limitations by viewing the non-GAAP financial measures in conjunction with the GAAP financial measures. In addition, the non-GAAP financial measures included in this earnings announcement may be different from, and therefore may not be comparable to, similar measures used by other companies.

Each of the non-GAAP financial measures listed above is also used by our management to evaluate our operating performance, communicate our financial results to our Board of Directors, benchmark our results against our historical performance and the performance of our peers, evaluate investment opportunities including acquisitions and discontinued operations, and determine the bonus payments for senior management and employees.

Contacts

Investor Relations:
Steve Willoughby (781) 663-5677
steve.willoughby@revvity.com

Media Contact:
Fara Goldberg (781) 663-5699
fara.goldberg@revvity.com

EX-101.SCH 3 pki-20230511.xsd XBRL TAXONOMY EXTENSION SCHEMA 000100 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink EX-101.DEF 4 pki-20230511_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 5 pki-20230511_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Class of Stock [Domain] Common Stock [Member] Class of Stock [Axis] Cover [Abstract] Document Type Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Amendment Flag Document Fiscal Year Focus Document Fiscal Period Focus Document Period End Date Entity Registrant Name Entity Central Index Key Entity File Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Emerging Growth Company Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code City Area Code Local Phone Number Entity Listings [Table] Entity Listings [Line Items] Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name 1.875% Notes due 2026 [Member] EX-101.PRE 6 pki-20230511_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 7 R1.htm IDEA: XBRL DOCUMENT v3.23.1
Document and Entity Information
May 11, 2023
Entity Listings [Line Items]  
Document Type 8-K
Amendment Flag false
Document Period End Date May 11, 2023
Entity File Number 001-05075
Entity Registrant Name REVVITY, INC.
Entity Central Index Key 0000031791
Entity Incorporation, State or Country Code MA
Entity Tax Identification Number 04-2052042
Entity Address, Address Line One 940 Winter Street
Entity Address, City or Town Waltham
Entity Address, State or Province MA
Entity Address, Postal Zip Code 02451
City Area Code 781
Local Phone Number 663-6900
Entity Emerging Growth Company false
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Common Stock [Member]  
Entity Listings [Line Items]  
Title of 12(b) Security Common stock, $1 par value per share
Trading Symbol PKI
Security Exchange Name NYSE
1.875% Notes due 2026 [Member]  
Entity Listings [Line Items]  
Title of 12(b) Security 1.875% Notes due 2026
Trading Symbol PKI 21A
Security Exchange Name NYSE
XML 8 a53397725_htm.xml IDEA: XBRL DOCUMENT 0000031791 2023-05-11 2023-05-11 0000031791 us-gaap:CommonStockMember 2023-05-11 2023-05-11 0000031791 pki:One875NotesDue2026Member 2023-05-11 2023-05-11 false REVVITY, INC. 0000031791 8-K 2023-05-11 MA 001-05075 04-2052042 940 Winter Street Waltham MA 02451 781 663-6900 false false false false Common stock, $1 par value per share PKI NYSE 1.875% Notes due 2026 PKI 21A NYSE false EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.1 html 3 22 1 false 2 0 false 0 false false R1.htm 000100 - Document - Document and Entity Information Sheet http://perkinelmer.com/role/DocumentAndEntityInformation Document and Entity Information Cover 1 false false All Reports Book All Reports [ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 1 fact(s) appearing in ix:hidden were eligible for transformation: dei:EntityRegistrantName - a53397725.htm 11 a53397725.htm a53397725ex99_1.htm pki-20230511.xsd pki-20230511_def.xml pki-20230511_lab.xml pki-20230511_pre.xml http://xbrl.sec.gov/dei/2021 true false JSON 15 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "a53397725.htm": { "axisCustom": 0, "axisStandard": 1, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2021": 25 }, "contextCount": 3, "dts": { "definitionLink": { "local": [ "pki-20230511_def.xml" ] }, "inline": { "local": [ "a53397725.htm" ] }, "labelLink": { "local": [ "pki-20230511_lab.xml" ] }, "presentationLink": { "local": [ "pki-20230511_pre.xml" ] }, "schema": { "local": [ "pki-20230511.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2004/ref-2004-08-10.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd", "https://xbrl.sec.gov/country/2021/country-2021.xsd", "https://xbrl.sec.gov/currency/2021/currency-2021.xsd", "https://xbrl.sec.gov/dei/2021/dei-2021.xsd", "https://xbrl.sec.gov/exch/2021/exch-2021.xsd", "https://xbrl.sec.gov/naics/2021/naics-2021.xsd", "https://xbrl.sec.gov/sic/2021/sic-2021.xsd", "https://xbrl.sec.gov/stpr/2021/stpr-2021.xsd" ] } }, "elementCount": 35, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2021": 3, "total": 3 }, "keyCustom": 0, "keyStandard": 22, "memberCustom": 1, "memberStandard": 1, "nsprefix": "pki", "nsuri": "http://perkinelmer.com/20230511", "report": { "R1": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "a53397725.htm", "contextRef": "c20230511to20230511", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "000100 - Document - Document and Entity Information", "menuCat": "Cover", "order": "1", "role": "http://perkinelmer.com/role/DocumentAndEntityInformation", "shortName": "Document and Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "a53397725.htm", "contextRef": "c20230511to20230511", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 2, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://perkinelmer.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://perkinelmer.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2021", "xbrltype": "stringItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://perkinelmer.com/role/DocumentAndEntityInformation" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://perkinelmer.com/role/DocumentAndEntityInformation" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://perkinelmer.com/role/DocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://perkinelmer.com/role/DocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://perkinelmer.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://perkinelmer.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://perkinelmer.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://perkinelmer.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://perkinelmer.com/role/DocumentAndEntityInformation" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://perkinelmer.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://perkinelmer.com/role/DocumentAndEntityInformation" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://perkinelmer.com/role/DocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://perkinelmer.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://perkinelmer.com/role/DocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://perkinelmer.com/role/DocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityListingsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Entity Listings [Line Items]" } } }, "localname": "EntityListingsLineItems", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://perkinelmer.com/role/DocumentAndEntityInformation" ], "xbrltype": "stringItemType" }, "dei_EntityListingsTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Container for exchange listing information for an entity", "label": "Entity Listings [Table]" } } }, "localname": "EntityListingsTable", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://perkinelmer.com/role/DocumentAndEntityInformation" ], "xbrltype": "stringItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://perkinelmer.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://perkinelmer.com/role/DocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://perkinelmer.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_NoTradingSymbolFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a security having no trading symbol.", "label": "No Trading Symbol Flag" } } }, "localname": "NoTradingSymbolFlag", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://perkinelmer.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://perkinelmer.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://perkinelmer.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://perkinelmer.com/role/DocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://perkinelmer.com/role/DocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://perkinelmer.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://perkinelmer.com/role/DocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://perkinelmer.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "pki_One875NotesDue2026Member": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "1.875% Notes due 2026 [Member]" } } }, "localname": "One875NotesDue2026Member", "nsuri": "http://perkinelmer.com/20230511", "presentation": [ "http://perkinelmer.com/role/DocumentAndEntityInformation" ], "xbrltype": "domainItemType" }, "us-gaap_ClassOfStockDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Class of Stock [Domain]" } } }, "localname": "ClassOfStockDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://perkinelmer.com/role/DocumentAndEntityInformation" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Common Stock [Member]" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://perkinelmer.com/role/DocumentAndEntityInformation" ], "xbrltype": "domainItemType" }, "us-gaap_StatementClassOfStockAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Class of Stock [Axis]" } } }, "localname": "StatementClassOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://perkinelmer.com/role/DocumentAndEntityInformation" ], "xbrltype": "stringItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r5": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425", "role": "http://www.xbrl.org/2003/role/presentationRef" } }, "version": "2.2" } ZIP 16 0001157523-23-000815-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001157523-23-000815-xbrl.zip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end